查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美體外診斷市場預測至 2030 年 - 區域分析 - 按產品和服務、技術、應用和最終用戶
市場調查報告書
商品編碼
1463559

北美體外診斷市場預測至 2030 年 - 區域分析 - 按產品和服務、技術、應用和最終用戶

North America In-Vitro Diagnostics Market Forecast to 2030 - Regional Analysis - by Product & Services, Technology, Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 112 Pages | 訂單完成後即時交付

價格

北美體外診斷市場預計將從2022年的212.0707億美元成長到2030年的331.8341億CAGR。

COVID-19 大流行期間床邊檢測的成長和 IVD 需求的激增推動了北美體外診斷市場

即時檢測 (POCT) 是體外診斷市場的關鍵機遇，以其攜帶式和快速的診斷能力徹底改變了醫療保健服務。這些測試在患者所在地或附近進行，可以立即提供結果，從而能夠及時做出臨床決策。有幾個因素推動 POCT 的成長。

首先，急診室、診所和家庭護理等醫療機構對方便快速的診斷解決方案的需求推動了 POCT 的擴張。其次，技術進步促進了緊湊且方便用戶使用的 POCT 設備的發展。

此外，COVID-19 大流行凸顯了快速、方便的診斷的重要性。這次疫情加速了 COVID-19 即時檢測的部署和利用，展示了 POCT 在全球範圍內管理傳染病的相關性和潛力。這項經驗加速了 POCT 的研發，進一步推動了攜帶式測試解決方案的創新和投資。

用於診斷傳染病的 IVD 包括免疫測定和分子測定。診斷公司也致力於快速改進其管理 COVID-19 的產品。此外，監管機構對其標準進行了臨時修訂或修改，這有利於在大流行期間推出新的體外診斷設備。由於這些政府舉措，對分子診斷和免疫測定的需求激增。因此，由於對即時診斷 (POC) 診斷和實驗室檢測程序的需求不斷成長，COVID-19 大流行使體外診斷市場受益。

北美體外診斷市場概況

北美地區包括美國、加拿大和墨西哥。按地理分類，它在體外診斷市場中佔有最大佔有率。該地區所有三個國家都見證了對體外診斷的巨大需求。某些因素，例如慢性病和傳染病的盛行率不斷上升、對有效疾病診斷的關注以及對先進醫療保健系統的更高需求，正在推動該地區體外診斷的採用。美國佔據北美體外診斷市場的最大佔有率。癌症和心血管疾病等慢性病是美國殘疾和死亡的主要原因。根據國家慢性病預防和健康促進中心的數據，全國十分之六的人至少患有一種慢性病。根據美國疾病管制與預防中心 (CDC) 的數據，2021 年，美國約有 1,820 萬名 20 歲及以上的成年人患有冠狀動脈疾病 (CAD)。心臟病是該國人民死亡的主要原因。此外，美國醫院協會估計約 1.33 億人至少患有一種慢性病，預計到 2030 年這一數字將達到 1.7 億人。對預防保健的日益重視以及醫療保健設施的普及將進一步推動未來幾年的市場成長。

隨著患者數量的不斷增加，對體外診斷工具的需求呈指數級成長，市場參與者專注於開發能夠快速檢查的先進診斷系統。例如，2019 年 2 月，美國診斷服務公司 Grail 獲得了微軟和亞馬遜 15 億美元的財務援助，旨在開發快速癌症檢測的新技術。此外，發達的醫療基礎設施和不斷增加的支出帶來的廣泛技術進步正在為該國體外診斷市場的成長創造利潤豐厚的機會。例如，2019年7月，體外診斷市場的知名參與者之一Sysmex America, Inc.在第71屆AACC年度科學會議和臨床實驗室博覽會上展示了其名為PS-10的新型整合體外診斷機在加州阿納海姆舉辦。該機器設計用於執行複雜的實驗室測試、常規細胞計數和血液學評估。同樣，2020 年 5 月，Bio-Rad Laboratories Inc. 的 SARS-CoV-2 液滴數位 PCR (ddPCR) 檢測試劑盒獲得美國食品藥物管理局 (FDA) 的緊急使用授權 (EUA)。 SARS-CoV-2 ddPCR 測試在 Bio-Rad 的 QX200 和 QXDx ddPCR 系統上運行。

北美體外診斷市場收入及 2030 年預測（百萬美元）

北美體外診斷市場細分

北美體外診斷市場分為產品和服務、技術、應用、最終用戶和國家。

根據產品和服務，北美體外診斷市場分為試劑和試劑盒、儀器以及軟體和服務。 2022年，試劑和試劑盒細分市場佔據北美體外診斷市場的最大佔有率。

根據技術，北美體外診斷市場分為免疫測定/免疫化學、臨床化學、分子診斷、微生物學、血糖自我監測、凝血和止血、血液學、尿液分析等。 2022 年，免疫分析/免疫化學領域佔據北美體外診斷市場的最大佔有率。

根據應用，北美體外診斷市場分為傳染病、糖尿病、腫瘤學、心臟病學、自體免疫疾病、腎臟病學等。 2022年，傳染病領域佔據北美體外診斷市場的最大佔有率。

根據最終用戶，北美體外診斷市場分為醫院、實驗室、家庭護理等。 2022年，醫院細分市場在北美體外診斷市場中佔據最大佔有率。

根據國家/地區，北美體外診斷市場分為美國、加拿大和墨西哥。 2022年，美國將主導北美體外診斷市場。

Abbott Laboratories、Becton Dickinson and Co、bioMerieux SA、Bio-Rad Laboratories Inc、Danaher Corp、F. Hoffmann-La Roche Ltd、Qiagen NV、Siemens AG、Sysmex Corp 和Thermo Fisher Scientific Inc 是在這些地區營運的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美體外診斷市場 - 主要產業動態

  • 主要市場促進因素
    • 慢性病和傳染病的盛行率不斷增加
    • COVID-19 大流行期間床邊檢測的成長和 IVD 需求的激增
  • 市場約束
    • 監理框架和報銷政策不足
  • 市場機會
    • IVD 與數位健康科技的整合
  • 未來的趨勢
    • 對個人化醫療和基因組學的需求不斷成長

第 5 章：體外診斷市場 - 北美市場分析

  • 北美體外診斷市場收入，2022 - 2030

第 6 章：北美體外診斷市場 - 2030 年收入和預測 - 按產品和服務

  • 概述
  • 2022 年和 2030 年北美體外診斷市場收入佔有率（按產品和服務分類）
  • 試劑和試劑盒
  • 軟體和服務
  • 儀器

第 7 章：北美體外診斷市場 - 收入和 2030 年預測 - 按技術分類

  • 概述
  • 北美體外診斷市場收入佔有率，按技術分類 2022 年和 2030 年 (%)
  • 免疫測定/免疫化學
  • 臨床化學
  • 分子診斷
  • 微生物學
  • 血糖自我監測
  • 凝血與止血
  • 血液學
  • 尿液分析
  • 其他

第 8 章：北美體外診斷市場 - 2030 年收入和預測 - 按應用

  • 概述
  • 2022 年和 2030 年北美體外診斷市場收入佔有率，按應用分類 (%)
  • 傳染病
  • 糖尿病
  • 腫瘤學
  • 心臟病學
  • 自體免疫疾病
  • 腎臟病學
  • 其他

第 9 章：北美體外診斷市場 - 收入和 2030 年預測 - 按最終用戶

  • 概述
  • 2022 年及 2030 年北美體外診斷市場收入佔有率（按最終用戶分類）（%）
  • 醫院
  • 實驗室
  • 居家護理
  • 其他

第 10 章：北美體外診斷市場 - 2030 年收入與預測 - 國家分析

  • 美國
  • 加拿大
  • 墨西哥

第 11 章：產業格局

  • 有機發展
    • 概述
  • 無機發展
    • 概述

第 12 章：公司簡介

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Danaher Corp
  • Siemens AG
  • Sysmex Corp
  • Thermo Fisher Scientific Inc
  • Becton Dickinson and Co
  • bioMerieux SA
  • Bio-Rad Laboratories Inc
  • Qiagen NV

第 13 章：附錄

Product Code: TIPRE00022125

The North America in-vitro diagnostics market is expected to grow from US$ 21,207.07 million in 2022 to US$ 33,183.41 million by 2030. It is estimated to grow at a CAGR of 5.8% from 2022 to 2030.

Growth in Point-of-Care Testing and Surge in Demand for IVD during COVID-19 Pandemic Fuels North America In-Vitro Diagnostics Market

Point-of-care testing (POCT) is a pivotal opportunity in the in vitro diagnostics market, revolutionizing healthcare delivery with its potable and rapid diagnostic capabilities. These tests, conducted at or near the patient's location, offer immediate results, enabling timely clinical decision-making. Several factors drive the growth of POCT.

Firstly, the demand for convenient and swift diagnostic solutions in healthcare settings, such as emergency rooms, clinics, and home care, propels the expansion of POCT. Secondly, technological advancements have led to the development of compact and user-friendly POCT devices.

Moreover, the COVID-19 pandemic underscored the significance of rapid and accessible diagnostics. The pandemic accelerated the deployment and utilization of point-of-care COVID-19 tests, showcasing the relevance and potential of POCT in managing infectious diseases on a global scale. This experience accelerated research and development on POCT, further driving innovation and investment in portable testing solutions.

IVDs that are used in the diagnosis of infectious diseases include immunoassays, and molecular assays. Diagnostics companies also focus on making rapid advancements in their offerings to manage COVID-19. Further, regulatory authorities introduced temporary amendments or modifications to their standards, which favored the launches of new IVDs during the pandemic. The demand for molecular diagnostics and immunoassays surged due to these government initiatives. Thus, the COVID-19 pandemic has benefitted the in-vitro diagnostics market due to the rising demand for point-of-care (POC) diagnostics and laboratory testing procedures.

North America In-Vitro Diagnostics Market Overview

North America region includes the US, Canada, and Mexico. It holds the largest share of the in-vitro diagnostics market by geography. All three countries in the region are witnessing considerable demand for in-vitro diagnostics. Certain factors, such as the increasing prevalence of chronic & infectious diseases, focus on efficient disease diagnosis, and a higher need for advanced healthcare systems are boosting the adoption of in-vitro diagnostics in the region. The US held the largest share of the North America in-vitro diagnostics market. Chronic diseases such as cancer and cardiovascular diseases are the major causes of disability and death in the US. Per the National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 people in the country have at least one chronic disease. According to the Centers for Disease Control and Prevention (CDC), in 2021, ~18.2 million adults aged 20 and above had coronary artery disease (CAD) in the US. Heart disease is the leading cause of death among people in the country. Additionally, the American Hospital Association estimates ~133 million people have at least one chronic disease, and that number is expected to reach 170 million by 2030. The high incidence of chronic diseases results in a huge demand for diagnostic procedures, which, in turn, drives the in-vitro diagnostics market in the US. Growing emphasis on preventive care coupled with enhanced access to healthcare facilities would further boost the market growth in the coming years.

With the exponentially rising need for in-vitro diagnostics tools with the growing patient pool, the market players focus on developing advanced diagnostic systems enabling rapid examinations. For instance, in February 2019, Grail, a US-based player in diagnostic services, received financial aid of US$ 1.5 billion from Microsoft and Amazon with an aim to develop new technologies for rapid cancer detection. Additionally, extensive technological advancements due to developed healthcare infrastructure and rising expenditure are generating lucrative opportunities for the growth of the in-vitro diagnostics market in the country. For instance, in July 2019, Sysmex America, Inc., one of the prominent players in the in-vitro diagnostics market, showcased its new integrated in-vitro diagnostic machine named PS-10 at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo organized in Anaheim, California. The machine is designed to perform complex laboratory tests, routine cytometry, and hematology assessments. Similarly, in May 2020, Bio-Rad Laboratories Inc. received Emergency Use Authorization (EUA) for its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit from the US Food and Drug Administration (FDA). The SARS-CoV-2 ddPCR test runs on Bio-Rad's QX200 and QXDx ddPCR systems.

North America In-Vitro Diagnostics Market Revenue and Forecast to 2030 (US$ Million)

North America In-Vitro Diagnostics Market Segmentation

The North America in-vitro diagnostics market is segmented into product & services, technology, application, end user, and country.

Based on product & services, the North America in-vitro diagnostics market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on technology, the North America in-vitro diagnostics market is segmented into immunoassay/ immunochemistry, clinical chemistry, molecular diagnostics, microbiology, blood glucose self-monitoring, coagulation & hemostasis, hematology, urinalysis, and others. The immunoassay/ immunochemistry segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on application, the North America in-vitro diagnostics market is segmented into infectious diseases, diabetes, oncology, cardiology, autoimmune diseases, nephrology, and others. The infectious diseases segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on end user, the North America in-vitro diagnostics market is segmented into hospitals, laboratories, homecare, and others. The hospitals segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on country, the North America in-vitro diagnostics market is segmented int o the US, Canada, and Mexico. The US dominated the North America in-vitro diagnostics market in 2022.

Abbott Laboratories, Becton Dickinson and Co, bioMerieux SA, Bio-Rad Laboratories Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Qiagen NV, Siemens AG, Sysmex Corp, and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America in-vitro diagnostics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America In-Vitro Diagnostics Market - Key Industry Dynamics

  • 4.1 Key Market Drivers
    • 4.1.1 Increasing Prevalence of Chronic and Infectious Diseases
    • 4.1.2 Growth in Point-of-Care Testing and Surge in Demand for IVD during COVID-19 Pandemic
  • 4.2 Market Restraint
    • 4.2.1 Insufficiency of Regulatory Frameworks and Reimbursement Policies
  • 4.3 Market Opportunities
    • 4.3.1 Integration of IVD with Digital Health Technologies
  • 4.4 Future Trends
    • 4.4.1 Increasing Demand for Personalized Medicine and Genomics

5. In-Vitro Diagnostics Market - North America Market Analysis

  • 5.1 North America In-Vitro Diagnostics Market Revenue (US$ Mn), 2022 - 2030

6. North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 - by Product and Services

  • 6.1 Overview
  • 6.2 North America In-Vitro Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
  • 6.3 Reagents and Kits
    • 6.3.1 Overview
    • 6.3.2 Reagents and Kits: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Software and Services
    • 6.4.1 Overview
    • 6.4.2 Software and Services: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Instruments
    • 6.5.1 Overview
    • 6.5.2 Instruments: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

7. North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 - by Technology

  • 7.1 Overview
  • 7.2 North America In-Vitro Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
  • 7.3 Immunoassay/ Immunochemistry
    • 7.3.1 Overview
    • 7.3.2 Immunoassay/ Immunochemistry: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Clinical Chemistry
    • 7.4.1 Overview
    • 7.4.2 Clinical Chemistry: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Molecular Diagnostics
    • 7.5.1 Overview
    • 7.5.2 Molecular Diagnostics: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Microbiology
    • 7.6.1 Overview
    • 7.6.2 Microbiology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Blood Glucose Self-Monitoring
    • 7.7.1 Overview
    • 7.7.2 Blood Glucose Self-Monitoring: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.8 Coagulation and Hemostasis
    • 7.8.1 Overview
    • 7.8.2 Coagulation and Hemostasis: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.9 Hematology
    • 7.9.1 Overview
    • 7.9.2 Hematology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.10 Urinalysis
    • 7.10.1 Overview
    • 7.10.2 Urinalysis: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.11 Others
    • 7.11.1 Overview
    • 7.11.2 Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

8. North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 - by Application

  • 8.1 Overview
  • 8.2 North America In-Vitro Diagnostics Market Revenue Share, by Application 2022 & 2030 (%)
  • 8.3 Infectious Disease
    • 8.3.1 Overview
    • 8.3.2 Infectious Diseases: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Diabetes
    • 8.4.1 Overview
    • 8.4.2 Diabetes: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Oncology
    • 8.5.1 Overview
    • 8.5.2 Oncology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Cardiology
    • 8.6.1 Overview
    • 8.6.2 Cardiology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.7 Autoimmune Diseases
    • 8.7.1 Overview
    • 8.7.2 Autoimmune Diseases: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.8 Nephrology
    • 8.8.1 Overview
    • 8.8.2 Nephrology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.9 Others
    • 8.9.1 Overview
    • 8.9.2 Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

9. North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 North America In-Vitro Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.3 Hospitals
    • 9.3.1 Overview
    • 9.3.2 Hospitals: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Laboratories
    • 9.4.1 Overview
    • 9.4.2 Laboratories: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Homecare
    • 9.5.1 Overview
    • 9.5.2 Homecare: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

10. North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 - Country Analysis

  • 10.1 North America In-Vitro Diagnostics Market
    • 10.1.1 Overview
    • 10.1.2 North America In-Vitro Diagnostics Market, by Country
      • 10.1.2.1 US: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.1.1 Overview
        • 10.1.2.1.2 US: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.1.3 US: North America In-Vitro Diagnostics Market, by Product and Services, 2020-2030 (US$ Million)
        • 10.1.2.1.4 US: North America In-Vitro Diagnostics Market, by Technology, 2020-2030 (US$ Million)
        • 10.1.2.1.5 US: North America In-Vitro Diagnostics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.2.1.6 US: North America In-Vitro Diagnostics Market, by End User, 2020-2030 (US$ Million)
      • 10.1.2.2 Canada: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.2.1 Overview
        • 10.1.2.2.2 Canada: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.2.3 Canada: North America In-Vitro Diagnostics Market, by Product and Services, 2020-2030 (US$ Million)
        • 10.1.2.2.4 Canada: North America In-Vitro Diagnostics Market, by Technology, 2020-2030 (US$ Million)
        • 10.1.2.2.5 Canada: North America In-Vitro Diagnostics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.2.2.6 Canada: North America In-Vitro Diagnostics Market, by End User, 2020-2030 (US$ Million)
      • 10.1.2.3 Mexico: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.3.1 Overview
        • 10.1.2.3.2 Mexico: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.3.3 Mexico: North America In-Vitro Diagnostics Market, by Product and Services, 2020-2030 (US$ Million)
        • 10.1.2.3.4 Mexico: North America In-Vitro Diagnostics Market, by Technology, 2020-2030 (US$ Million)
        • 10.1.2.3.5 Mexico: North America In-Vitro Diagnostics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.2.3.6 Mexico: North America In-Vitro Diagnostics Market, by End User, 2020-2030 (US$ Million)

11. Industry Landscape

  • 11.1 Organic Developments
    • 11.1.1 Overview
  • 11.2 Inorganic Developments
    • 11.2.1 Overview

12. Company Profiles

  • 12.1 Abbott Laboratories
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 F. Hoffmann-La Roche Ltd
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Danaher Corp
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Siemens AG
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Sysmex Corp
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Thermo Fisher Scientific Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Becton Dickinson and Co
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 bioMerieux SA
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Bio-Rad Laboratories Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Qiagen NV
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America In-Vitro Diagnostics Market Segmentation
  • Table 2. US North America In-Vitro Diagnostics Market, by Product and Services - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. US North America In-Vitro Diagnostics Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. US North America In-Vitro Diagnostics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. US North America In-Vitro Diagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. Canada North America In-Vitro Diagnostics Market, by Product and Services - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. Canada North America In-Vitro Diagnostics Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. Canada North America In-Vitro Diagnostics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Canada North America In-Vitro Diagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Mexico North America In-Vitro Diagnostics Market, by Product and Services - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Mexico North America In-Vitro Diagnostics Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Mexico North America In-Vitro Diagnostics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Mexico North America In-Vitro Diagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Organic Developments Done by Companies
  • Table 15. Inorganic Developments Done by Companies
  • Table 16. Glossary of Terms, North America In-Vitro Diagnostics Market

List Of Figures

  • Figure 1. North America In-Vitro Diagnostics Market Segmentation, By Country
  • Figure 2. North America In-Vitro Diagnostics Market: Key Industry Dynamics
  • Figure 3. North America In-Vitro Diagnostics Market: Impact Analysis of Drivers and Restraints
  • Figure 4. North America In-Vitro Diagnostics Market Revenue (US$ Mn), 2020 - 2030
  • Figure 5. North America In-Vitro Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
  • Figure 6. Reagents and Kits: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Software and Services: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Instruments: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America In-Vitro Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
  • Figure 10. Immunoassay/ Immunochemistry: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Clinical Chemistry: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Molecular Diagnostics: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Microbiology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Blood Glucose Self-Monitoring: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Coagulation and Hemostasis: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Hematology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Urinalysis: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. North America In-Vitro Diagnostics Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 20. Infectious Diseases: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Diabetes: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Oncology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Cardiology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Autoimmune Diseases: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Nephrology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 26. Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 27. North America In-Vitro Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 28. Hospitals: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. Laboratories: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 30. Homecare: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 31. Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 32. North America: North America In-Vitro Diagnostics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 33. North America In-Vitro Diagnostics Market, by Country, 2022 & 2030 (%)
  • Figure 34. US: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 35. Canada: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 36. Mexico: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)